Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

NCT00299871 · Completed

Last updated 2026-05-28

This clinical trial tested different doses of the medication AVE0010, a GLP-1 agonist, in adults with type 2 diabetes who were already taking metformin, to see how it affects blood sugar levels over 13 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 542 people

Who can join Ages 30–75 · all sexes

Timeline Started 2006-02 · est. completion 2007-08

Where 7 sites · Brazil, Canada, Poland, Romania, Russia, Ukraine, United States

What this study is testing ClinicalTrials.gov NCT00299871 ↗

Description as written by the study sponsor.

To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes

Treatments tested

LIXISENATIDE (AVE0010) Drug

Main thing measured	HbA1c levels at baseline and endpoint (at 13 weeks).
Sponsor	Sanofi
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00299871 ↗